![Dear Freddie](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dear Freddie
Private Equity Investor bei
Monograph Capital Advisors (UK) LLP
Profil
Freddie Dear is currently working as a Principal at Monograph Capital Advisors (UK) LLP since 2021.
He is also serving as the Vice President-Corporate Development at Ascend Gene & Cell Therapies Ltd. since 2022.
Previously, Freddie worked as an Operations Director at Quell Therapeutics Ltd. from 2019 to 2020.
He also held the position of Partner at Syncona Partners LLP from 2018 to 2021.
Freddie completed his undergraduate degree from The University of Edinburgh in 2016.
Aktive Positionen von Dear Freddie
| Unternehmen | Position | Beginn |
|---|---|---|
Monograph Capital Advisors (UK) LLP
 Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital invests in companies located in the United Kingdom. The firm targets companies operating in the fields of the biotechnology and healthcare sectors. It provides financing for early and growth stage capital requirements. | Private Equity Investor | 01.12.2021 |
Ascend Gene & Cell Therapies Ltd.
 Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology research and development center | Corporate Officer/Principal | 01.12.2021 |
Ehemalige bekannte Positionen von Dear Freddie
| Unternehmen | Position | Ende |
|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Private Equity Investor | 31.12.2021 |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Geschäftsführer | 31.03.2020 |
Ausbildung von Dear Freddie
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
84
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
The University of Edinburgh
 The University of Edinburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Finance |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Health Technology |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital invests in companies located in the United Kingdom. The firm targets companies operating in the fields of the biotechnology and healthcare sectors. It provides financing for early and growth stage capital requirements. | Finance |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology research and development center | Commercial Services |
